Forest Laboratories encounters setbacks on 2 drugs

03/8/2009 | Forbes

Forest Laboratories said it is postponing the launch of fibromyalgia treatment Savella until midyear, when the FDA is expected to respond to changes that Forest and partner Cypress Biosciences made to the drug's formula. Forest also announced that it will delay its application for FDA approval of aclidinium bromide, its candidate for chronic obstructive pulmonary disease, until additional clinical trials have been conducted.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ
Director, Site Quality Management
Minneapolis, MN
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC